Skip to main content

Table 3 Relationship between immunochemical features and tumor grade

From: Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

Target expression Low-grade, % High-grade, % p-value Target expression Low-grade, % High-grade, % p-value
VEGFA     APOE    
1 4 (16.7%) 43 (30.9%) 0.031 1 6 (25.0%) 24 (14.7%) 0.598
2 3 (12.5%) 40 (28.8%)   2 5 (20.8%) 39 (23.9%)  
3 7 (29.2%) 30 (21.6%)   3 5 (20.8%) 46 (28.2%)  
4 10 (41.7%) 26 (18.7%)   4 8 (33.3%) 54 (33.1%)  
MMP9     SERPINA1    
1 3 (12.5%) 10 (6.5%) 0.161 1 2 (9.1%) 32 (20.4%) 0.021
2 9 (37.5%) 36 (23.5%)   2 10 (45.5%) 27 (17.2%)  
3 8 (33.3%) 50 (32.7%)   3 5 (22.7%) 43 (27.4%)  
4 4 (16.7%) 57 (37.3%)   4 5 (22.7%) 55 (35.0%)  
MMP10     SDC1    
1 7 (29.2%) 29 (19.0%) 0.611 1 2 (8.0%) 25 (15.7%) 0.222
2 3 (12.5%) 32 (20.9%)   2 3 (12.0%) 31 (19.5%)  
3 6 (25.0%) 39 (25.5%)   3 7 (28.0%) 53 (33.3%)  
4 8 (33.3%) 53 (34.6%)   4 13 (52.0%) 50 (31.4%)  
SERPINE1     ANG    
1 10 (41.7%) 34 (22.4%) 0.213 1 0 (0%) 4 (2.5%) 0.783
2 4 (16.7%) 27 (17.8%)   2 7 (29.2%) 47 (28.8%)  
3 5 (20.8%) 38 (25.0%)   3 7 (29.2%) 56 (34.4%)  
4 5 (20.8%) 53 (34.9%)   4 10 (41.7%) 56 (34.4%)  
IL8        
1 9 (37.5%) 43 (26.2%) 0.699     
2 4 (16.7%) 37 (22.6%)      
3 4 (16.7%) 32 (19.5%)      
4 7 (29.2%) 52 (31.7%)      
CA9        
1 7 (30.4%) 28 (16.9%) 0.206     
2 6 (26.1%) 40 (24.1%)      
3 2 (8.7%) 43 (25.9%)      
4 8 (34.8%) 55 (33.1%)